Organ transplantation. Transplanted organ and tissue status
Conditions
Interventions
Intervention 1: The intervention group received the HTK perfusion solution (Cmab Fare Zist Inc., Shiraz, Iran) according to routine transplantation protocol. Intervention 2: The control group received
Sponsors
Pharmed Cina Caspian Pouyesh Company
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: Patient undergoing liver transplantation Age above 18 years old Informed consent to enter the study
Exclusion criteria
Exclusion criteria: Those with organ donations from outside of the province Pregnant patients or those who are lactating Those with donations after cardiac death (DCD) Those who are undergoing re-transplantations Those with machine perfusion
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary non-function of organ. Timepoint: 30 days after transplantation. Method of measurement: Blood tests and pathology biopsy. | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in AST and ALT on the first day after transplantation up to discharge. Timepoint: One day after transplantation up to discharge. Method of measurement: Blood test.;Acute rejection during first month. Timepoint: One month after transplantation. Method of measurement: Blood tests and pathology biopsy.;Early patient survival (3 months). Timepoint: Three months after transplantation. Method of measurement: Follow-up of patients and hospital records.;Biliary complications. Timepoint: Three months after transplantation. Method of measurement: follow-up sonography. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAlireza Shamsaeefar
Shiraz University of Medical Sciences
Outcome results
None listed